Ahmet Seyda Yilmaz, Abdulkadir Uslu, Faruk Kara, Fatih Kahraman, Omer Faruk Cirakoglu
{"title":"急性冠脉综合征患者血清纤维蛋白肽A升高。","authors":"Ahmet Seyda Yilmaz, Abdulkadir Uslu, Faruk Kara, Fatih Kahraman, Omer Faruk Cirakoglu","doi":"10.14744/nci.2021.12499","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Acute coronary syndrome (ACS) is one of the leading causes of mortality, globally. Atherosclerosis is an underlying factor in ACS process and coagulative cascade is activated secondary to atherosclerotic plaque rupture. Fibrinopeptide A (FPA) takes an active role in thrombus formation and is an indicator of coagulative process. We aimed to evaluate serum FPA level in patients with ACS.</p><p><strong>Methods: </strong>Patients diagnosed with ACS and chronic coronary syndrome (CCS), with non-obstructive coronary artery disease as a control group, were included in the study. Blood samples and demographic data of all patients were obtained at admission. Obtained data were compared between ACS and control groups.</p><p><strong>Results: </strong>The study consisted of 107 patients with ACS and 69 patients with CCS. ACS group was older (p<0.001) with male preponderance (p<0.001), more likely to had hypertension (p<0.001), and had a higher smoking rate (p<0.001). Serum FPA level was highest in the ST elevated myocardial infarction group (p<0.001). FPA>3.38 ng/mL predicted ACS with 89.7% sensitivity and 78% specificity (AUC: 0.825, 95% CI 0.745-0.905; p<0.001).</p><p><strong>Conclusion: </strong>Serum FPA may be used for the differential diagnosis of ACS. In addition, patients with increased FPA may be considered to be given more aggressive antithrombotic medication.</p>","PeriodicalId":19164,"journal":{"name":"Northern Clinics of Istanbul","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/17/07/NCI-10-017.PMC9996658.pdf","citationCount":"0","resultStr":"{\"title\":\"Serum fibrinopeptide A is increased in patients with acute coronary syndrome.\",\"authors\":\"Ahmet Seyda Yilmaz, Abdulkadir Uslu, Faruk Kara, Fatih Kahraman, Omer Faruk Cirakoglu\",\"doi\":\"10.14744/nci.2021.12499\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Acute coronary syndrome (ACS) is one of the leading causes of mortality, globally. Atherosclerosis is an underlying factor in ACS process and coagulative cascade is activated secondary to atherosclerotic plaque rupture. Fibrinopeptide A (FPA) takes an active role in thrombus formation and is an indicator of coagulative process. We aimed to evaluate serum FPA level in patients with ACS.</p><p><strong>Methods: </strong>Patients diagnosed with ACS and chronic coronary syndrome (CCS), with non-obstructive coronary artery disease as a control group, were included in the study. Blood samples and demographic data of all patients were obtained at admission. Obtained data were compared between ACS and control groups.</p><p><strong>Results: </strong>The study consisted of 107 patients with ACS and 69 patients with CCS. ACS group was older (p<0.001) with male preponderance (p<0.001), more likely to had hypertension (p<0.001), and had a higher smoking rate (p<0.001). Serum FPA level was highest in the ST elevated myocardial infarction group (p<0.001). FPA>3.38 ng/mL predicted ACS with 89.7% sensitivity and 78% specificity (AUC: 0.825, 95% CI 0.745-0.905; p<0.001).</p><p><strong>Conclusion: </strong>Serum FPA may be used for the differential diagnosis of ACS. In addition, patients with increased FPA may be considered to be given more aggressive antithrombotic medication.</p>\",\"PeriodicalId\":19164,\"journal\":{\"name\":\"Northern Clinics of Istanbul\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/17/07/NCI-10-017.PMC9996658.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Northern Clinics of Istanbul\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14744/nci.2021.12499\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Northern Clinics of Istanbul","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/nci.2021.12499","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
目的:急性冠脉综合征(ACS)是全球范围内导致死亡的主要原因之一。动脉粥样硬化是ACS过程的一个潜在因素,在动脉粥样硬化斑块破裂后,凝血级联被激活。纤维蛋白肽A (fibrinep肽A, FPA)在血栓形成中起积极作用,是凝血过程的指标。我们的目的是评估ACS患者血清FPA水平。方法:以ACS合并慢性冠脉综合征(CCS)患者为研究对象,以非阻塞性冠状动脉病变患者为对照组。入院时采集所有患者的血液样本和人口统计资料。ACS组与对照组比较所得数据。结果:本研究纳入107例ACS患者和69例CCS患者。ACS组年龄较大(p3.38 ng/mL预测ACS,敏感性89.7%,特异性78%)(AUC: 0.825, 95% CI 0.745-0.905;结论:血清FPA可用于ACS的鉴别诊断。此外,FPA升高的患者可以考虑给予更积极的抗血栓药物治疗。
Serum fibrinopeptide A is increased in patients with acute coronary syndrome.
Objective: Acute coronary syndrome (ACS) is one of the leading causes of mortality, globally. Atherosclerosis is an underlying factor in ACS process and coagulative cascade is activated secondary to atherosclerotic plaque rupture. Fibrinopeptide A (FPA) takes an active role in thrombus formation and is an indicator of coagulative process. We aimed to evaluate serum FPA level in patients with ACS.
Methods: Patients diagnosed with ACS and chronic coronary syndrome (CCS), with non-obstructive coronary artery disease as a control group, were included in the study. Blood samples and demographic data of all patients were obtained at admission. Obtained data were compared between ACS and control groups.
Results: The study consisted of 107 patients with ACS and 69 patients with CCS. ACS group was older (p<0.001) with male preponderance (p<0.001), more likely to had hypertension (p<0.001), and had a higher smoking rate (p<0.001). Serum FPA level was highest in the ST elevated myocardial infarction group (p<0.001). FPA>3.38 ng/mL predicted ACS with 89.7% sensitivity and 78% specificity (AUC: 0.825, 95% CI 0.745-0.905; p<0.001).
Conclusion: Serum FPA may be used for the differential diagnosis of ACS. In addition, patients with increased FPA may be considered to be given more aggressive antithrombotic medication.